Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma

We present our initial experience in using single modality fluoromisonidazole (FMISO) PET/MR imaging to noninvasively evaluate the biological effects induced by bevacizumab therapy in a patient treated for recurrent high grade glioma. In this index patient, bevacizumab therapy resulted in the develo...

Descripción completa

Detalles Bibliográficos
Autores principales: Barajas, Ramon F., Pampaloni, Miguel H., Clarke, Jennifer L., Seo, Youngho, Savic, Dragana, Hawkins, Randall A., Behr, Spencer C., Chang, Susan M., Berger, Mitchel, Dillon, William P., Cha, Soonmee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352456/
https://www.ncbi.nlm.nih.gov/pubmed/25793136
http://dx.doi.org/10.1155/2015/731361
_version_ 1782360457473949696
author Barajas, Ramon F.
Pampaloni, Miguel H.
Clarke, Jennifer L.
Seo, Youngho
Savic, Dragana
Hawkins, Randall A.
Behr, Spencer C.
Chang, Susan M.
Berger, Mitchel
Dillon, William P.
Cha, Soonmee
author_facet Barajas, Ramon F.
Pampaloni, Miguel H.
Clarke, Jennifer L.
Seo, Youngho
Savic, Dragana
Hawkins, Randall A.
Behr, Spencer C.
Chang, Susan M.
Berger, Mitchel
Dillon, William P.
Cha, Soonmee
author_sort Barajas, Ramon F.
collection PubMed
description We present our initial experience in using single modality fluoromisonidazole (FMISO) PET/MR imaging to noninvasively evaluate the biological effects induced by bevacizumab therapy in a patient treated for recurrent high grade glioma. In this index patient, bevacizumab therapy resulted in the development of nonenhancing tumor characterized by reduced diffusion and markedly decreased FMISO uptake in the setting of maintained CBF and CBV. These observations suggest that the dynamic biological interplay between tissue hypoxia and vascular normalization occurring within treated recurrent high grade glioma can be captured utilizing FMISO PET/MR imaging.
format Online
Article
Text
id pubmed-4352456
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-43524562015-03-19 Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma Barajas, Ramon F. Pampaloni, Miguel H. Clarke, Jennifer L. Seo, Youngho Savic, Dragana Hawkins, Randall A. Behr, Spencer C. Chang, Susan M. Berger, Mitchel Dillon, William P. Cha, Soonmee Case Rep Radiol Case Report We present our initial experience in using single modality fluoromisonidazole (FMISO) PET/MR imaging to noninvasively evaluate the biological effects induced by bevacizumab therapy in a patient treated for recurrent high grade glioma. In this index patient, bevacizumab therapy resulted in the development of nonenhancing tumor characterized by reduced diffusion and markedly decreased FMISO uptake in the setting of maintained CBF and CBV. These observations suggest that the dynamic biological interplay between tissue hypoxia and vascular normalization occurring within treated recurrent high grade glioma can be captured utilizing FMISO PET/MR imaging. Hindawi Publishing Corporation 2015 2015-02-22 /pmc/articles/PMC4352456/ /pubmed/25793136 http://dx.doi.org/10.1155/2015/731361 Text en Copyright © 2015 Ramon F. Barajas Jr. et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Barajas, Ramon F.
Pampaloni, Miguel H.
Clarke, Jennifer L.
Seo, Youngho
Savic, Dragana
Hawkins, Randall A.
Behr, Spencer C.
Chang, Susan M.
Berger, Mitchel
Dillon, William P.
Cha, Soonmee
Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma
title Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma
title_full Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma
title_fullStr Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma
title_full_unstemmed Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma
title_short Assessing Biological Response to Bevacizumab Using 18F-Fluoromisonidazole PET/MR Imaging in a Patient with Recurrent Anaplastic Astrocytoma
title_sort assessing biological response to bevacizumab using 18f-fluoromisonidazole pet/mr imaging in a patient with recurrent anaplastic astrocytoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352456/
https://www.ncbi.nlm.nih.gov/pubmed/25793136
http://dx.doi.org/10.1155/2015/731361
work_keys_str_mv AT barajasramonf assessingbiologicalresponsetobevacizumabusing18ffluoromisonidazolepetmrimaginginapatientwithrecurrentanaplasticastrocytoma
AT pampalonimiguelh assessingbiologicalresponsetobevacizumabusing18ffluoromisonidazolepetmrimaginginapatientwithrecurrentanaplasticastrocytoma
AT clarkejenniferl assessingbiologicalresponsetobevacizumabusing18ffluoromisonidazolepetmrimaginginapatientwithrecurrentanaplasticastrocytoma
AT seoyoungho assessingbiologicalresponsetobevacizumabusing18ffluoromisonidazolepetmrimaginginapatientwithrecurrentanaplasticastrocytoma
AT savicdragana assessingbiologicalresponsetobevacizumabusing18ffluoromisonidazolepetmrimaginginapatientwithrecurrentanaplasticastrocytoma
AT hawkinsrandalla assessingbiologicalresponsetobevacizumabusing18ffluoromisonidazolepetmrimaginginapatientwithrecurrentanaplasticastrocytoma
AT behrspencerc assessingbiologicalresponsetobevacizumabusing18ffluoromisonidazolepetmrimaginginapatientwithrecurrentanaplasticastrocytoma
AT changsusanm assessingbiologicalresponsetobevacizumabusing18ffluoromisonidazolepetmrimaginginapatientwithrecurrentanaplasticastrocytoma
AT bergermitchel assessingbiologicalresponsetobevacizumabusing18ffluoromisonidazolepetmrimaginginapatientwithrecurrentanaplasticastrocytoma
AT dillonwilliamp assessingbiologicalresponsetobevacizumabusing18ffluoromisonidazolepetmrimaginginapatientwithrecurrentanaplasticastrocytoma
AT chasoonmee assessingbiologicalresponsetobevacizumabusing18ffluoromisonidazolepetmrimaginginapatientwithrecurrentanaplasticastrocytoma

Ejemplares similares